

L&G Healthcare Breakthrough UCITS ETF

ETF (UCITS compliant) USD Accumulating ETF Class



FUND AIM

The L&G Healthcare Breakthrough UCITS ETF (the "ETF") aims to track the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the "Index"). More information on the Index can be found on page 2 of this document.

RISK AND REWARD PROFILE



This ETF is rated 6 due to the nature of its investments and its risks.

The rating is calculated based on historical data and may not be a reliable indication of the ETF's future risk profile.

The risk category may shift over time.

The lowest category on the above scale does not mean "risk free."

WHO IS THIS FUND FOR?

- This ETF is designed for investors looking to grow their money in an investment which can form part of their existing savings portfolio
- Although investors can take their money out at any time, this ETF may not be appropriate for those who plan to withdraw their money within five years
- If you do not understand the information in this document, the key investor information document or the prospectus, we recommend that you seek additional information or advice to help you decide if this ETF is suitable for you.


FUND FACTS

Fund size	Base currency	Index	
\$97.4m	USD	ROBO Global® Healthcare Technology and Innovation Index	
Listing date	Domicile	Index ticker	Replication method
2 Jul 2019	Ireland	HTECTR	Physical - full replication

COSTS

Total expense ratio
0.49%

PERFORMANCE (%) IN USD



	1 month	6 months	1 year	3 years	Launch
NAV	10.29	42.37	65.72	-	81.37
Index	10.32	42.78	66.55	-	82.78
Relative	-0.03	-0.41	-0.83	-	-1.41

ANNUAL PERFORMANCE (%)

12 Months to 31 December	2020	2019	2018	2017	2016
NAV	65.72	-	-	-	-
Index	66.55	-	-	-	-
Relative	-0.83	-	-	-	-

Performance for the USD Accumulating ETF class, listed on 2 July 2019. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF.

Past performance is not a guide to the future.

FUND SNAPSHOT

- **Long-term allocation**
Long-term megatrend that we believe is radically transforming the way we live and work
- **High growth potential**
Aims to capture the outsized growth potential of the healthcare technology industry
- **Leveraging industry expertise**
An index tracking investment strategy that is supported by a team of healthcare technology experts


INDEX BREAKDOWN

The breakdowns below relate to the Index. The ETF's portfolio may deviate from the below. All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding.



SECTOR (%)

Medical Instruments	26.8
Diagnostics	13.4
Precision Medicine	13.1
Process Automation	12.6
Genomics	9.3
Data Analytics	9.2
Robotics	5.5
Telehealth	5.4
Regenerative Medicine	4.6



CURRENCY (%)

USD	84.3
EUR	6.2
CHF	3.7
GBP	1.8
HKD	1.4
AUD	1.1
DKK	0.8
JPY	0.7



■ Top 10 constituents 17.4%
 ■ Rest of Index 82.6%
 No. of constituents in Index 82

TOP 10 CONSTITUENTS (%)

Editas Medicine	2.8
Irhythm Technologies	1.8
Abiomed	1.7
Vocera Communications	1.6
Integra Lifesciences	1.6
Cardiovascular Systems	1.6
Natera	1.6
Tabula Rasa HealthCare	1.6
Health Catalyst	1.6
Fulgent Genetics	1.5

INDEX DESCRIPTION

The Index aims to track the performance of a basket of companies that are actively engaged in the healthcare technology value-chain.

The index is comprised of companies which are publicly traded on various stock exchanges around the world that have a distinct portion of their business and revenue derived from the field of healthcare technologies, and the potential to grow within this space through innovation and/or market adoption of their products and/or services. Companies are included in the index receive a "HTEC Score" comprised of factors representing (1) the levels of revenue the company receives from innovative healthcare technologies, (2) the levels of investment the firm makes in healthcare technologies, (3) the market and technology leadership of the firm within the universe.

A company is only eligible for inclusion in the Index if it is of a sufficient size (determined by reference to the total market value of its shares) and it is sufficiently "liquid" (a measure of how actively its shares are traded on a daily basis). Within the Index, companies are weighted according a modified HTEC-factor weighting scheme. The Index is rebalanced quarterly in March, June, September and December.

INVESTMENT MANAGER

GO ETF Solutions LLP is the investment manager for each of the exchange traded funds (ETFs) issued by Legal & General UCITS ETF Plc and is responsible for the day-to-day investment management decisions for this ETF. The team is highly experienced with respect to all aspects relating to the management of an ETF portfolio, including collateral management, OTC swap trading, adherence to UCITS regulations and counterparty exposure and monitoring.

KEY RISKS

- The value of an investment and any income taken from it is not guaranteed and can go down as well as up; you may not get back the amount you originally invested.
- Third party service providers (such as counterparties entering into financial derivative instruments with the ETF or the ETF's depository) may go bankrupt and fail to pay money due to the ETF or return property belonging to the ETF.
- As the Index includes micro, small and medium-sized publicly traded companies, the ETF is subject to the risk that such companies may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies or the stock market as a whole.
- The ETF is subject to the risks associated with technology-focused companies that are particularly vulnerable to rapid developments in technology (which may leave their products out-of-date), government regulation and competition from domestic and foreign competitors who may have lower production costs. Such companies may also have difficulties establishing and maintaining patents, copyrights, trademarks and trade secrets relating to their products which could negatively affect their value.
- It may not always be possible to buy and sell ETF shares on a stock exchange or at prices closely reflecting the NAV.
- If the Index provider stops calculating the Index or if the ETF's license to track the Index is terminated, the ETF may have to be closed.

For more information, please refer to the key investor information document on our website [↗](#)

TRADING INFORMATION

Exchange	Currency	ISIN	SEDOL	Ticker	Bloomberg
London Stock Exchange	USD	IE00BK5BC677	BKF3JJ5	DOCT	DOCT LN
London Stock Exchange	GBX	IE00BK5BC677	BKF3JQ2	DOCG	DOCG LN
Borsa Italiana	EUR	IE00BK5BC677	BKF3JG2	DOCT	DOCT IM
Deutsche Börse	EUR	IE00BK5BC677	BKF3DF9	XMLH	XMLH GY
SIX Swiss Exchange	CHF	IE00BK5BC677	BMG6920	DOCT	DOCT SW

The currency shown is the trading currency of the listing.



SPOTLIGHT ON LEGAL & GENERAL INVESTMENT MANAGEMENT

We are one of Europe's largest asset managers and a major global investor, with assets under management of £1,240.6 billion (as at 30 June 2020). We work with a wide range of global clients, including pension schemes, sovereign wealth funds, fund distributors and retail investors.

Source: LGIM internal data as at 30 June 2020. The AUM disclosed aggregates the assets managed by LGIM in the UK, LGIMA in the US and LGIM Asia in Hong Kong. The AUM includes the value of securities and derivatives positions.

COUNTRY REGISTRATION

Austria	Denmark	Finland
France	Germany	Ireland
Italy	Luxembourg	Netherlands
Norway	Spain	Sweden
Switzerland	United Kingdom	

AVAILABILITY

ISA eligible	Yes
SIPP eligible	Yes
UK Fund Reporting Status	Yes

TO FIND OUT MORE

Visit [lgimETF.com](https://www.lgimETF.com)

Call **0345 070 8684**

Email fundsales@lgim.com

Lines are open Monday to Friday 8.30am to 6.00pm.
We may record and monitor calls. Call charges will vary.

Index Disclaimer

The L&G Healthcare Breakthrough UCITS ETF (the "ETF") is not sponsored, promoted, sold or supported in any other manner by ROBO Global LLC or Solactive AG (the "Index Parties"), nor do the Index Parties offer any express or implicit guarantee either with regard to the results of using the ROBO Global® Healthcare Technology and Innovation Index (the "Index") and/or Index trademark or the Index price at any time or in any other respect. The Index is calculated and published by Solactive AG. The Index Parties use their best efforts to ensure that the Index is calculated correctly. Irrespective of their obligations towards the Company, the Index Parties have no obligation to point out errors in the Index to third parties including but not limited to investors and/or financial intermediaries of the ETF. Neither publication of the Index by Solactive AG nor the licensing of the Index or Index trademark by ROBO Global LLC for the purpose of use in connection with the ETF constitutes a recommendation by the Index Parties to invest capital in the ETF nor does it in any way represent an assurance or opinion of the Index Parties with regard to any investment in the ETF.

Important Information

In the United Kingdom and outside the European Economic Area, this document is issued by Legal & General Investment Management Limited, authorised and regulated by the Financial Conduct Authority, No. 119272. Registered in England and Wales No. 02091894 with registered office at One Coleman Street, London, EC2R 5AA.

In the European Economic Area, this document is issued by LGIM Managers (Europe) Limited, authorised by the Central Bank of Ireland as a UCITS management company (pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (S.I. No. 352 of 2011), as amended) and as an alternative investment fund manager with "top up" permissions which enable the firm to carry out certain additional MiFID investment services (pursuant to the European Union (Alternative Investment Fund Managers) Regulations 2013 (S.I. No. 257 of 2013), as amended). Registered in Ireland with the Companies Registration Office (No. 609677). Registered Office: 33/34 Sir John Rogerson's Quay, Dublin, 2, Ireland. Regulated by the Central Bank of Ireland (No. C173733).

LGIM Managers (Europe) Limited operates a branch network in the European Economic Area, which is subject to supervision by the Central Bank of Ireland. In Italy, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Commissione Nazionale per le società e la Borsa ("CONSOB") and is registered with Banca d'Italia (no. 23978.0) with registered office at Via Uberto Visconti di Modrone, 15, 20122 Milan, (Companies' Register no. MI - 2557936). In Germany, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the German Federal Financial Supervisory Authority ("BaFin"). In the Netherlands, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Dutch Authority for the Financial Markets ("AFM") and it is included in the register held by the AFM and registered with the trade register of the Chamber of Commerce under number 74481231. Details about the full extent of our relevant authorisations and permissions are available from us upon request. For further information on our products (including the product prospectuses), please visit our website.

The shares (the "Shares") discussed in this document are issued in relation to the relevant sub-fund (or share class(es) thereof) described in this document (together, the "Fund").

Copyright © 2021 Legal & General. This document is subject to copyright. Any unauthorised use is strictly prohibited. All rights are reserved.

No investment advice: We are required to clarify that we are not acting for you in any way in relation to the investment or investment activity to which this document relates. In particular, we will not provide any investment services to you and/or advise you on the merits of, or make any recommendation to you in relation to, the terms of any transaction. None of our representatives are authorised to behave in any way which would lead you to believe otherwise. We are not, therefore, responsible for providing you with the protections afforded to some of our clients and you should seek your own independent legal, investment and tax or other advice as you see fit.

United States information: This document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the Fund or the Shares are authorised or registered for distribution and where no prospectus of the Fund has been filed with any securities commission or regulatory authority. Neither this document nor any copy hereof should be taken, transmitted or distributed (directly or indirectly) into the United States. Neither the Fund nor any of the Shares have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

No guarantee of accuracy: This document may contain independent market commentary prepared by us based on publicly available information. We do not warrant, guarantee or otherwise confirm the accuracy or correctness of any information contained herein and any opinions related to product or market activity may change. Any third party data providers used to source the information in this document make no warranties or claims of any kind relating to such data.

Historical performance is no indication of future performance: Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. However, back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance.

No offer for sale: The information contained in this document is neither an offer for sale nor a solicitation of an offer to buy securities. This document should not be used as the basis for any investment decision.

Risk Warnings: The Shares are products involving a significant degree of risk and may not be suitable for all types of investor. Any decision to invest should be based on the information contained in the prospectus of the Fund (or any supplements thereto) which includes, inter alia, information on certain risks associated with an investment. The price of any securities may go up or down and an investor may not get back the amount invested. Investors should only invest in a currency-hedged share class if they are willing to forego potential gains from appreciations in the currencies in which the Fund's assets are denominated against the currency of denomination of the relevant hedged share class. Currency hedging employed with respect to the hedged share classes aims to reduce currency risk rather than to eliminate it completely. Investors should also refer to the risk factor entitled "Currency" in the section of the Prospectus entitled "Risk Factors."

Prospectus: Investors should refer to the section entitled "Risk Factors" in the Fund's prospectus for further details of these and other risks associated with an investment in the Shares. The information in this document is designed solely for use in the relevant countries in which the Fund has been registered for public distribution and is not intended for residents of any other countries. The distribution of the prospectus and the offering, sale and delivery of Shares in other jurisdictions may be restricted by law.

For United Kingdom investors: The Fund is a recognised scheme under section 264 of the Financial Services and Markets Act 2000 and so the prospectus may be distributed to investors in the United Kingdom. Copies of all documents (i.e. the prospectus, the key investor information document, the latest annual audited report and financial statements and semi-annual unaudited report and financial statements and the constitution) are available in the United Kingdom from www.lgimetc.com.

For Austrian investors: Investors should base their investment decision only on the relevant prospectus, the Key Investor Information Document, any supplements or addenda thereto, copies of the Memorandum and Articles of Association and the annual and semi-annual report, which can be obtained free of charge upon request at the Paying and Information Agent in Austria, Erste Bank der oesterreichischen Sparkassen AG, Graben 21, 1010 Wien, Österreich and on www.lgimetc.com.

For Dutch investors: The Fund has been registered with the Netherlands Authority for the Financial Markets following the UCITS passport-procedure pursuant to section 2:72 of the Dutch Financial Supervision Act.

For French investors: In France, this material is intended exclusively for professional investors (as defined under the MIFID) investing for their own account and this material may not in any way be distributed to the public. The Fund is a UCITS governed by Irish legislation and approved by the Central Bank of Ireland as UCITS compliant with European regulations although may not have to comply with the same rules as those applicable to a similar product approved in France. The Fund has been registered for marketing in France by the Authority Financial Markets (Autorité des Marchés Financiers) and may be distributed to investors in France. Copies of all documents (i.e. the prospectus, any supplements or addenda thereto, the latest annual reports, the memorandum of incorporation and articles of association and Key Investor Information Document) are available in France, free of charge, at the French Centralizing Agent, Société Générale, Securities Services, at 1-5 rue du Débarcadère, 92700 Colombes - France. Any subscription for Shares of the Fund will be made on the basis of the terms of the prospectus and any supplements or addenda thereto.

For German investors: Investors should base their investment decision only on the relevant prospectus and the Key Investor Information Document. The offering of the Shares of the Fund has been notified to the German Financial Services Supervisory Authority (BaFin) in accordance with section 310 of the German Investment Code (KAGB). The Key Investor Information Document (in the German language), the prospectus, any supplements or addenda thereto, copies of the Memorandum and Articles of Association and the annual and semi-annual report, can be obtained free of charge upon request at the Paying and Information Agent in Germany, HSBC Trinkaus & Burkhardt AG, Königsallee 21-23, 40212 Düsseldorf and on www.lgimetc.com. The current offering and redemption prices as well as the net asset value and possible notifications of the investors can also be requested free of charge at the same address. This document is a marketing communication within the meaning of Section 63 para. 6 of the German Securities Trading Act (WpHG). It is not investment research within the meaning of Art. 36 of the Commission Delegated Regulation (EU) 2017/565 and therefore does not meet all legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

For Norwegian Investors: The Fund has been registered with the Financial Supervisory Authority of Norway (Finanstilsynet), and may be marketed and sold to professional investors in Norway.

For Swiss investors: The Fund described in this document will be distributed in Switzerland exclusively to qualified investors as defined in the Swiss Collective Investment Schemes Act and its implementing ordinance. The representative and paying agent in Switzerland is State Street Bank International GmbH, Munich, Zurich Branch, Beethovenstrasse 19, 8027 Zurich, Switzerland. The prospectus, the key investor information document, the articles of association and the annual and semi-annual reports relating to the Fund are available free of charge from the representative in Switzerland. As regards distribution in Switzerland, the place of jurisdiction and performance is at the registered seat of the representative.